# Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

> **NCT03314051** · — · COMPLETED · sponsor: **Taichung Veterans General Hospital** · enrollment: 366 (actual)

## Conditions studied

- Nasopharyngeal Carcinoma
- EBV Related Carcinoma

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT03314051
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05-02
- **Primary completion:** 2013-05-01
- **Final completion:** 2016-12-31
- **Target enrollment:** 366 (ACTUAL)
- **Last updated:** 2017-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03314051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03314051, "Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03314051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*